SCHEMBL23099385

SCHEMBL23099385

CC(CCCCNC=O)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.47
BLM P54132 1/20 0.47
ADH1B P00325 4/20 0.45
ADH1A P07327 4/20 0.45
ADH7 P40394 3/20 0.45
ADH1C P00326 3/20 0.45
ACE2 Q9BYF1 1/20 0.44
GABRR1 P24046 2/20 0.43
CYP1A2 P05177 1/20 0.43
EPHX1 P07099 1/20 0.43
ADH4 P08319 1/20 0.43
TBXAS1 P24557 2/20 0.38
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
CA1 P00915 1/20 0.35
FOLH1 Q04609 1/20 0.34
NAALAD2 Q9Y3Q0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25905661 0.96 BLM (0.47) LTA4HBLMADH1BADH1AADH7
SCHEMBL17017527 0.88 GABRR1 (0.52) LTA4HBLMADH1BADH1AADH7
SCHEMBL7179523 0.80 BLM (0.65) LTA4HBLMACE2GABRR1CYP1A2
SCHEMBL16330413 0.80 BLM (0.65) LTA4HBLMACE2GABRR1CYP1A2
SCHEMBL9910890 0.79 LTA4H (0.50) LTA4HBLMACE2GABRR1CYP1A2
SCHEMBL23981544 0.79 LTA4H (0.50) LTA4HBLMACE2GABRR1CYP1A2
SCHEMBL9333340 0.79 LTA4H (0.50) LTA4HBLMACE2GABRR1CYP1A2
SCHEMBL3587010 0.78 BLM (0.50) LTA4HBLMACE2GABRR1CYP1A2
SCHEMBL18272798 0.78 ACE2 (0.52) LTA4HBLMACE2GABRR1CYP1A2
SCHEMBL9001608 0.78 ACE2 (0.64) LTA4HBLMACE2GABRR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11872262-B2 Means and methods for treating bacterial infections VIB VZW (BE) 2024-01-16 US disclosed
US-11872262-B2 Means and methods for treating bacterial infections VIB VZW (BE) 2024-01-16 US disclosed
US-20210077563-A1 Means and Methods for Treating Bacterial Infections VIB VZW (BE) 2021-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210077563-A1 Means and Methods for Treating Bacterial Infections VIP, MMP8, SLC11A2 LTA4H 915/4885BLM 1975/4885ADH1B 4221/4885
US-11872262-B2 Means and methods for treating bacterial infections VIP, MMP8, SLC11A2 LTA4H 915/4885BLM 1975/4885ADH1B 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.